CALTH. Inc Logo

CALTH. Inc

Develops AI-powered rapid diagnostic solutions for point-of-care and self-testing.

402420 | KO

Overview

Corporate Details

ISIN(s):
KR7402420004
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 창업로 54, 321호(시흥동, 기업성장센터), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CALTH Inc. is an in vitro diagnostics (IVD) company that develops and manufactures rapid diagnostic solutions. The company provides innovative healthcare services for point-of-care testing (POCT), self-testing, and precision medicine. Its core business is built upon two proprietary technologies: an "Engineered Nanotrap" system for high-sensitivity sample preprocessing and a deep learning-based algorithm for the rapid and accurate analysis of Lateral Flow Assay products. CALTH's mission is to improve quality of life by delivering fast, accurate, and low-cost diagnostic tools. The company operates in facilities certified with KGMP and ISO 13485:2016.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-11 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-11 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-11 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 82.8 KB
2025-08-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 88.1 KB
2025-08-06 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.2 KB
2025-07-29 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 35.1 KB
2025-07-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.2 KB
2025-07-17 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 54.6 KB
2025-06-19 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.8 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 16.4 KB
2025-03-21 00:00
Audit Report / Information
감사보고서제출
Korean 10.1 KB
2025-03-21 00:00
Annual Report
사업보고서 (2024.12)
Korean 971.9 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 103.1 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 7.5 KB
2025-02-06 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 5.8 KB

Automate Your Workflow. Get a real-time feed of all CALTH. Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CALTH. Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CALTH. Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

SOLIGENIX, INC. Logo
Late-stage biopharma developing treatments for rare diseases and public health threats.
United States of America
SNGX
Sonnet BioTherapeutics Holdings, Inc. Logo
Develops targeted cytokine therapies for cancer using a proprietary albumin-binding platform.
United States of America
SONN
Sonoma Pharmaceuticals, Inc. Logo
Develops and sells stabilized HOCl products for wound, skin, eye, nasal, and animal healthcare.
United States of America
SNOA
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria
SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden
SPAGO
Spero Therapeutics, Inc. Logo
Develops novel treatments for multi-drug resistant bacterial infections and rare diseases.
United States of America
SPRO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB
Spyre Therapeutics, Inc. Logo
Engineering advanced antibody therapies for IBD and other immune diseases.
United States of America
SYRE

Talk to a Data Expert

Have a question? We'll get back to you promptly.